SCHEMBL20204073

SCHEMBL20204073

NC(=O)c1cc2nnc(C(F)(F)F)n2nc1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 5/20 0.55
CYP1A2 P05177 4/20 0.55
SCN1A P35498 1/20 0.47
SCN2A Q99250 1/20 0.47
CHEK1 O14757 1/20 0.42
ALPI P09923 1/20 0.39
ALDH1A1 P00352 2/20 0.39
SCN9A Q15858 3/20 0.37
FPR2 P25090 1/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
MAPK8 P45983 1/20 0.37
MAPK10 P53779 1/20 0.37
DYRK1A Q13627 1/20 0.37
DHODH Q02127 1/20 0.36
BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20190576 0.90 SCN5A (0.56) SCN5ACYP1A2SCN1ASCN2AALPI
SCHEMBL20190854 0.85 SCN5A (0.51) SCN5ACYP1A2SCN1ASCN2A
SCHEMBL20191029 0.82 SCN5A (0.61) SCN5ACYP1A2SCN1ASCN2AALDH1A1
SCHEMBL26539438 0.81 SCN5A (0.46) SCN5ACYP1A2SCN1ASCN2AALPI
SCHEMBL20203952 0.81 SCN5A (0.62) SCN5ACYP1A2SCN1ASCN2AALDH1A1
SCHEMBL20190617 0.80 SCN5A (0.61) SCN5ACYP1A2SCN1ASCN2AALDH1A1
SCHEMBL20190474 0.80 SCN5A (0.61) SCN5ACYP1A2SCN1ASCN2AALDH1A1
SCHEMBL20203975 0.79 SCN5A (0.52) SCN5ACYP1A2SCN1ASCN2AALPI
SCHEMBL20203983 0.79 SCN5A (0.57) SCN5ACYP1A2SCN1ASCN2AALDH1A1
SCHEMBL23571895 0.79 SCN5A (0.64) SCN5ACYP1A2SCN1ASCN2ACHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 US disclosed
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 US disclosed
WO-2018098499-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B SCN5A 8/4885CYP1A2 1988/4885SCN1A 1/4885
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B SCN5A 8/4885CYP1A2 1988/4885SCN1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.